Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02422797

Enrollment

518

Registered

2015-04-21

Start date

2015-04-21

Completion date

2023-05-25

Last updated

2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV, NNRTI-sparing, two-drug regimen, nucleoside reverse transcriptase inhibitors, protease inhibitor, integrase inhibitor, non-nucleoside reverse transcriptase inhibitor, dolutegravir plus rilpivirine, virologically-suppressed

Brief summary

The aim of this study was to determine if virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors \[NRTIs\] plus a third agent) remain suppressed upon switching to a two-drug regimen with dolutegravir (DTG) + rilpivirine (RPV). The study primarily assessed the non-inferiority antiviral activity of switching to DTG + RPV once daily compared to the continuation of current antiretroviral regimen (CAR) up to Week 48 with a switch visit for eligible subjects in the CAR group to initiate DTG + RPV therapy at Week 52. CAR included 2 NRTIs plus 1 HIV-1 integrase inhibitor (INI), or 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), or 1 protease inhibitor (PI). The study included a 148-week open-label treatment phase, comprising of an Early Switch Phase (Day 1 to Week 52) and a Late Switch Phase (Week 52 to Week 148). The participants fulfilling the study eligibility criteria participated in the Early Switch Phase where they either switched from their CAR to DTG + RPV, or continued taking their CAR, until Week 52. At the end of Early Switch Phase, eligible participants proceeded to the Late Switch Phase where all participants in both DTG + RPV and CAR treatment groups received DTG + RPV therapy until Week 148. After Week 148, subjects could have been eligible to continue to receive DTG +RPV in the Continuation Phase.

Interventions

DRUGDTG 50 mg

Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.

DRUGRPV 25 mg

Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase. Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.

DRUGCAR

CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions. * Participants must have been likely to complete the study as planned. * Participants must have been considered appropriate candidates for participation in an investigative clinical trial with oral medication (e.g., no active substance abuse, acute major organ disease, or planned long-term work assignments out of the country, etc.). * HIV-1 infected men or women of greater than or equal to (\>=)18 years of age. * Must have been on uninterrupted current regimen (either the initial or second combination antiretroviral therapy \[cART\] regimen) for at least 6 months prior to screening; Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability and/or safety concerns or access to medications, or convenience/simplification. Acceptable stable cART regimens prior to screening include 2 NRTIs plus INI (either the initial or second cART regimen), or an NNRTI (either the initial or second cART regimen), or a Boosted PI (or atazanavir unboosted) (either the initial or second PI-based cART regimen). * Documented evidence of at least two plasma HIV-1 RNA measurements \<50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month window, and one within 6 months prior to Screening; * Plasma HIV-1 RNA \<50 c/mL at Screening; * A female may have been eligible to enter and participate in the study if she was of : Non-child-bearing potential either defined as post-menopausal (12 months of spontaneous amenorrhea and \>=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, Child-bearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the following methods of contraception to avoid pregnancy: Complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for at least 2 weeks after discontinuation of all study medications and completion of the Follow-up visit; Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year (not all IUDs meet this criterion); Male partner sterilization with documentation of azoospermia prior to the female participant's entry into the study and this male is the sole partner for that participant; The documentation on male sterility could come from the site personnel's review of participant's medical records, medical examination, and/or semen analysis, or medical history interview provided by her or her partner; Approved hormonal contraception for participants randomly assigned to DTG + RPV arm (and for participants randomly assigned to CAR following switch to DTG + RPV at Week 52) or approved hormonal contraception plus a barrier method for participants assigned to CAR through Week 52; Approved hormonal contraception included: Combined estrogen and progestogen oral contraceptive, Contraceptive subdermal implant, Injectable progestogen, Contraceptive vaginal ring, Percutaneous contraceptive patches. Any other method with published data showing that the expected failure rate is \<1% per year. Any contraception method must have been used consistently, in accordance with the approved product label during treatment with study drug and for at least 2 weeks after discontinuation of study drug and completion of the Follow-Up Visit. The investigator was responsible for ensuring that participants understand how to properly use these methods of contraception. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal were not acceptable methods of contraception. * Participants who were willing and able to understand requirements of study participation and provided signed and dated written informed consent prior to screening. * For participants enrolled in France: participants were eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusionary Criteria prior to screening or Day 1: * Within 6 months prior to Screening and after confirmed suppression to \<50 c/mL on current ART regimen, any plasma HIV-1 RNA measurement \>=50 c/mL. * Within the 6 to 12 month window prior to screening and after confirmed suppression to \<50 c/mL, any plasma HIV-1 RNA measurement \>200 c/mL. * Within the 6 to 12 month window prior to screening and after confirmed suppression to \<50 c/mL, 2 or more plasma HIV-1 RNA measurements \>=50 c/mL. * Any drug holiday during the window between initiating first HIV ART and 6 months prior to screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns. * Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV 1 RNA measurement \>=400 c/mL after initial suppression to \<50 c/mL while on first line HIV therapy regimen). Exclusionary medical conditions: * Women who were pregnant, breastfeeding or planned to become pregnant or breastfeed during the study. * Any evidence of an active Centers for Disease Control and Prevention Category C disease. Exceptions included cutaneous Kaposi's sarcoma not requiring systemic therapy and historic CD4+ lymphocyte counts of \<200 cells per cubic millimeter (cells/mm\^3). * Participants with severe hepatic impairment (Class C) as determined by Child-Pugh Classification. * Unstable liver disease (as defined by the presence of any of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface antibody (HBsAb) as follows: Participants positive for HBsAg were excluded; Participants positive for anti-HBc (negative HBsAg status) and negative for HBsAb were excluded. * Participants with an anticipated need for any Hepatitis C virus (HCV) therapy during the Early Switch Phase and for interferon-based therapy for HCV throughout the entire study period. * History or presence of allergy to the study drugs or their components or drugs of their class; * Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the participant prior to randomization; * Participants who in the investigator's judgment posed a significant suicidality risk. Participant's history of suicidal behavior and/or suicidal ideation should have been considered when evaluating for suicide risk; * Any pre-existing physical or mental condition which, in the opinion of the Investigator, could have interfered with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which could have compromised the safety of the participants; * Any condition which, in the opinion of the Investigator, could have interfered with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to take oral medication; Exclusionary Treatments prior to Screening or Day 1: * Use of medications which were associated with Torsades de Pointes. * Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. * Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses. * Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study. * Participants who were participating or anticipated to be selected to participate in any other interventional study, with the exception of the DEXA sub-study 202094, after randomization * A history of use of any regimen consisting of only single NNRTI therapy (even if only for peri-partum treatment), or only single or dual NRTI therapy prior to starting cART. * Current or prior history of etravirine (ETR) use. * Current use of tipranavir/ritonavir or fosamprenavir/ritonavir. * Participants receiving any prohibited medication and who were unwilling or unable to switch to an alternate medication. Exclusionary Laboratory Values or Clinical Assessments at Screening: * Evidence of viral resistance based on the presence of any resistance associated major PI, INI, NRTI, or NNRTI mutation and integrase (IN) resistance associated substitution R263K in any available prior resistance genotype assay results. * Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities. A single repeat test was allowed during the Screening period to verify a result. * Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound. * Alanine aminotransferase (ALT) \>=5 × upper limit of normal (ULN), or ALT \>=3 × ULN and bilirubin \>=1.5 × ULN (with greater than \[\>\] 35% direct bilirubin). * Corrected QT interval (QTc \[Bazett\]) \>450 milliseconds or QTc (Bazett) \>480 milliseconds for participants with bundle branch block. The QTc was the QT interval corrected for heart rate according to Bazett's formula (QTcB).

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm	Week 48	Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior antiviral activity of switching to DTG+RPV once daily compared to continuation of CAR over 48 weeks in HIV-1 infected antiretroviral therapy (ART)-experienced participants. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

Secondary

Measure	Time frame	Description
Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	Week 52 to Week 410	For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain genotype data on as many samples as possible. Number of participants with genotypic resistance to CAR for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.
Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	Up to Week 410	Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential genotypic evolution of resistance. Genotypic Resistance data for the following drugs was presented: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.
Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	Up to Week 410	Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential phenotypic evolution of resistance. Phenotypic Resistance data for the following drugs was presented: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.
Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	Week 52 to Week 410	Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential phenotypic evolution of resistance. Phenotypic Resistance data for the following drugs was presented: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.
Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	Week 52 to Week 410	Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential phenotypic evolution of resistance. Phenotypic resistance data for the following drugs was presented: DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.
Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48	At Weeks 24 and 48	Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunological activity of DTG + RPV once daily compared to continuation of CAR. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Number of Participants With Phenotypic Resistance-Early Switch Phase	Up to Week 52	Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, RAL, EVG, RPV, ETR, 3TC, ABC, FTC, TDF, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, SQV/r, TPV/r) in participants Meeting CVW criteria has been presented.
Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 24 Using Snapshot Algorithm	Week 24	Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity of DTG +RPV once daily compared to continuation of CAR. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Up to Week 410 or study discontinuation	An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE. AEs were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading. Grade 1=mild; Grade 2=moderate, Grade 3=severe and Grade 4=potentially life-threatening. Common AEs were those with \>5% incidence for either treatment.
Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Up to 48 weeks	Blood samples were collected to evaluate alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, glucose, potassium, phosphate, sodium, blood urea nitrogen (BUN), total carbon dioxide, lipase, creatine phosphokinase and creatinine clearance. Value obtained at Day 1 was considered as Baseline value. Number of participants who experienced maximum grade toxicity post-baseline in clinical chemistry over 48 weeks was summarized. Clinical chemistry toxicities were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; Grade 2=moderate, Grade 3=severe and Grade 4=potentially life-threatening. For all laboratory parameters, one assessment out of range was sufficient to be considered a chemistry toxicity.
Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Up to 48 weeks	Blood samples were collected to evaluate hemoglobin, hematocrit, basophils, eosinophils, lymphocytes, monocytes, neutrophils, mean corpuscular volume (MCV), red blood cell (RBC) count, white blood cell (WBC) count and platelet count. Value obtained at Day 1 was considered as Baseline value. Number of participants who experienced maximum grade toxicity post-baseline in hematology over 48 weeks was summarized. Hematology toxicities were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; Grade 2=moderate, Grade 3=severe and Grade 4=potentially life-threatening. For all laboratory parameters, one assessment out of range was sufficient to be considered a hematology toxicity.
Mean Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess hs-CRP. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Cystatin C at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess cystatin C. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in D-Dimer at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess D-Dimer. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess FABP and soluble CD14. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess soluble CD163 and oxidized LDL. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess RBP, serum creatinine and glucose. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Urine Phosphate at Week 48	At Week 48	Urine biomarker samples were collected to at Baseline (Day 1) and Week 48 to assess urine phosphate. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess B2M and 25 hydroxy-vitamin D. Urine biomarker samples were collected to assess B2M and RBP. Change from Baseline was calculated as value at indicated time point minus Baseline value. For 25 hydroxy-vitamin D, analysis of changes from Baseline was performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios.
Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48	At Week 48	Urine biomarker samples were collected at Baseline (Day 1) and Week 48 to assess urine albumin/creatinine ratio and urine protein/creatinine ratio. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess bone-specific alkaline phosphatase, procollagen 1 N-terminal propeptide, osteocalcin, Type 1 Collagen C-telopeptides and sVCAM. Change from Baseline was calculated as value at indicated time point minus Baseline value. For bone-specific alkaline phosphatase, procollagen 1-N-propeptide, osteocalcin and type 1 collagen C-telopeptide, analyses of changes from Baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios.
Mean Change From Baseline in Interleukin 6 (IL-6) at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess IL-6. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Mean Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Week 48	At Week 48	Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess insulin resistance. Change from Baseline was calculated as value at indicated time point minus Baseline value. The homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR ) index , the product of basal glucose and insulin levels divided by 22.5, is regarded as a simple, inexpensive, and reliable surrogate measure of insulin resistance.
Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	At Weeks 24 and 48	Blood samples were collected at Baseline (Day 1), Week 24 and Week 48 to assess fasting lipids which included total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Number of Participants With Genotypic Resistance-Early Switch Phase	Up to Week 48	Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (Rilpivirine \[RPV\], Dolutegravir \[DTG\]) in participants Meeting Confirmed Virologic Withdrawal (CVW) criteria has been presented.
Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	Up to Week 148	Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW criteria has been presented.
Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	Up to Week 148	Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (DTG, Elvitegravir \[EVG\], Raltegravir \[RAL\], Delavirdine \[DLV\], Efavirenz \[EFV\], Etravirine \[ETR\], Nevirapine \[NVP\], RPV, Lamivudine \[3TC\], Abacavir \[ABC\], FTC, TDF, Zidovudine \[ZDV\], Stavudine \[d4T\], Didanosine \[ddI\], Atazanavir/r \[ATV/r\], DRV/r, Fosamprenavir/r \[FPV/r\], Indinavir/r \[IDV/r\], Lopinavir/r \[LPV/r\], Nelfinavir \[NFV\], Ritonavir \[RTV\], Saquinavir/r \[SQV/r\], Tipranavir/r \[TPV/r\]) in participants Meeting Confirmed Virologic Withdrawal Criteria has been presented.
Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	Post-Late switch (LS) Baseline (Week 52) up to Week 148	Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW Criteria has been presented.
Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	Post-LS Baseline (Week 52) up to Week 148	Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW criteria has been presented.
Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Pre-dose at Week 4, 24, 48, 56, 76 and 100	Two separate blood samples for DTG and RPV were collected pre-dose at Weeks 4, 24, 48, 56, 76 and 100. Pre-dose concentrations of DTG and RPV at Weeks 4, 24, 48, 56, 76 and 100 is summarized for the participants switching to DTG + RPV in the early+late switch phase.
Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Pre-dose at Weeks 56, 76 and 100	Two separate blood samples for DTG and RPV were collected pre-dose at Weeks 56, 76 and 100. Pre-dose concentrations of DTG and RPV at Weeks 56, 76 and 100 is summarized for the participants switching to DTG + RPV in the late switch phase.
Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Pre-dose at Weeks 2, 4 and 8	Two blood samples were collected pre-dose for DTG and RPV at Weeks 2 and 8 only for the first 20 participants who switch from EFV or NVP to DTG+RPV, in addition to the pre-dose blood sample collected at Week 4 for all participants. One blood sample was collected pre-dose for EFV or NVP at Week 2 for the first 20 participants who switch from EFV or NVP to DTG + RPV. PK Parameter NNRTI Subset Extra Sampling Population consisted of the first approximately 20 participants in the PK Parameter NNRTI Subset population who have extra PK samples at weeks 2 and 8.
Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	At Week 48	Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 48 using the FDA snapshot algorithm was assessed by Baseline third agent class to assess the impact of Baseline third agent class (INSTI, NNRTI, or PI) on efficacy, safety and tolerability of DTG +RPV compared to continuation of CAR. Plasma samples were collected for HIV-1 RNA at Baseline (Day 1), Week 4, 8, 12, 24, 36 and 48. The analysis was done using Cochran-Mantel Haenszel test stratified by current antiretroviral third-agent class.
Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	At Week 48	Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out at Baseline (Day 1) and Week 48 to assess the impact of Baseline third agent class (INSTI, NNRTI, or PI) on efficacy, safety and tolerability of DTG +RPV compared to continuation of CAR. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Up to 48 weeks	An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any AE, AELD or AE with maximum grade toxicity experienced by any one participant over 48 weeks by Baseline third agent class (INSTI, NNRTI, or PI) is summarized. AEs were graded using the Division of AIDS grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening.
Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	Up to 48 weeks	Blood samples were collected at Baseline (Day 1) and at Weeks 4, 8, 12, 24, 36 and 48 to evaluate ALT, albumin, ALP, AST, total bilirubin, chloride, creatinine, glucose, potassium, phosphate, sodium, BUN, total carbon dioxide, lipase, creatine phosphokinase and creatinine clearance. Number of participants who experienced maximum toxicity grade post-baseline in chemistry parameters over 48 weeks by Baseline third agent treatment class (INSTI, NNRTI, PI) is summarized. Clinical chemistry toxicities were graded using the DAIDS grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening.
Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	Up to 48 weeks	Blood samples were collected at Baseline (Day 1) and at Weeks 4, 8, 12, 24, 36 and 48 to evaluate hemoglobin, hematocrit, basophils, eosinophils, lymphocytes, monocytes, neutrophils, MCV, RBC count, WBC count and platelet count. Number of participants who experienced maximum toxicity grade post-baseline in hematology parameters over 48 weeks by Baseline third agent treatment class (INSTI, NNRTI, PI) was summarized. Hematology toxicities were graded using the DAIDS grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening.
Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class	Week 48	For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were to be analyzed in an attempt to obtain genotype data on as many samples as possible. Samples for drug resistance testing (genotypic) were to be collected at Day 1. Number of participants with genotypic resistance to CAR and to DTG or RPV for those meeting virologic withdrawal criteria in subgroups stratified based on Baseline third agent treatment class (INSTI, NNRTI, PI) were to be summarized.
Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class	Week 48	For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were to be analyzed in an attempt to obtain phenotype data on as many samples as possible. Samples for drug resistance testing (phenotypic) were to be collected at Day 1. Number of participants with phenotypic resistance to CAR and to DTG or RPV for those meeting virologic withdrawal criteria in subgroups stratified based on Baseline third agent treatment class (INSTI, NNRTI, PI) were to be summarized.
Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	At Weeks 24 and 48	Blood samples were collected at Baseline (Day 1), Weeks 24 and 48 to assess fasting lipids which included total cholesterol (CHO), LDL cholesterol, HDL cholesterol and triglycerides. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	At Weeks 4, 24 and 48	The Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in the participant and is the sum of the number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on the score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). Last observation carried forward (LOCF) was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	At Weeks 56, 76, 100 and 148	The Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in the participant and is the sum of the number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on the score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). LOCF was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	At Weeks 56, 76, 100 and 148	The Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in the participant and is the sum of the number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on the score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). LOCF was used as primary method of analysis. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value.
Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	At Weeks 4, 24 and 48	The HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 to 6 where a higher score indicates the greater improvement in the past few weeks. These items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscales: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). The HIV TSQ was administered as a paper questionnaire. Total score, lifestyle/ease score and General satisfaction/clinical sub-score (CS) have been summarized. LOCF was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	At Weeks 56, 76, 100 and 148	The HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Change from Baseline is calculated as the value at specified time point minus Baseline value. Total score, lifestyle/ease score and General satisfaction/clinical sub-score (CS) have been summarized. LOCF was used as primary method of analysis.
Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	At Weeks 56, 76, 100 and 148	The HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Change from LS Baseline is calculated as the value at specified time point minus LS Baseline value. Total score, lifestyle/ease score and General satisfaction/CS have been summarized. LOCF was used as primary method of analysis.
Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	Up to Week 410	For all participants who met virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain genotype data on as many samples as possible. Samples for drug resistance testing (genotypic) were collected at Day 1. Number of participants with genotypic resistance to DTG or RPV for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.
Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	Up to Week 410	For all participants who met virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain phenotype data on as many samples as possible. Samples for drug resistance testing (phenotypic) were collected at Day 1. Number of participants with phenotypic resistance to DTG or RPV for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.
Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	Week 52 to Week 410	For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain phenotype data on as many samples as possible. Number of participants with phenotypic resistance to CAR for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.

Other

Measure	Time frame	Description
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-CAR Group Through Late Switch Phase	Weeks 100 and 148	Plasma samples were collected for quantitative analysis of HIV-1 RNA. Percentage of participants with plasma HIV 1 RNA \< 50 c/mL using the FDA snapshot algorithm was assessed. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest.
Change From LS Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-CAR Group Through Late Switch Phase	LS Baseline (Week 48), Weeks 100 and 148	Blood samples were collected for CD4+ cell count assessment by flow cytometry. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value.
Change From Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	At Weeks 100 and 148	Blood samples were collected for CD4+ cell count assessment by flow cytometry. Change from Baseline was calculated as value at indicated time point minus Baseline value.
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-DTG+RPV Group Through Early and Late Switch Phase	Weeks 100 and 148	Plasma samples were collected for quantitative analysis of HIV-1 RNA. Percentage of participants with plasma HIV 1 RNA \< 50 c/mL using the FDA snapshot algorithm was assessed. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest.

Countries

Argentina, Australia, Canada, France, Germany, Italy, Russia, Spain, Taiwan, United Kingdom, United States

Participant flow

Recruitment details

The study was conducted at 60 centers in 11 countries.

Pre-assignment details

518 participants were randomized and 2 participants withdrew before being exposed to study drug. The study included an Early Switch Phase, a Late Switch Phase, and a Continuation Phase.

Participants by arm

Arm	Count
DTG + RPV Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase. Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148).	261
Current Antiretroviral Regimen (CAR) Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitor \[NRTIs\] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) \<50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed-up through the Late Switch Phase, at Week 148 and through the Continuation Phase, after Week 148.	255
Total	516

Withdrawals & dropouts

Period	Reason	FG000	FG001
Continuation Phase(Week 148 to Week 410)	Adverse Event	0	2
Continuation Phase(Week 148 to Week 410)	Investigator discretion	1	2
Continuation Phase(Week 148 to Week 410)	Lack of Efficacy	1	1
Continuation Phase(Week 148 to Week 410)	Lost to Follow-up	0	3
Continuation Phase(Week 148 to Week 410)	Protocol Violation	0	1
Continuation Phase(Week 148 to Week 410)	Subject reached protocol-defined stopping criteria	1	0
Continuation Phase(Week 148 to Week 410)	Withdrawal by Subject	4	1
Early Switch Phase (Up to Week 52)	Adverse Event	11	1
Early Switch Phase (Up to Week 52)	Lack of Efficacy	1	2
Early Switch Phase (Up to Week 52)	Lost to Follow-up	1	1
Early Switch Phase (Up to Week 52)	Physician Decision	0	1
Early Switch Phase (Up to Week 52)	Protocol Violation	0	3
Early Switch Phase (Up to Week 52)	Reached stopping criteria	1	1
Early Switch Phase (Up to Week 52)	Withdrawal by Subject	2	7
Late Switch Phase (Week 52 to Week 148)	Adverse Event	10	6
Late Switch Phase (Week 52 to Week 148)	Lack of Efficacy	5	3
Late Switch Phase (Week 52 to Week 148)	Lost to Follow-up	2	2
Late Switch Phase (Week 52 to Week 148)	Physician Decision	0	1
Late Switch Phase (Week 52 to Week 148)	Protocol Violation	3	0
Late Switch Phase (Week 52 to Week 148)	Reached stopping criteria	1	0
Late Switch Phase (Week 52 to Week 148)	Withdrawal by Subject	2	6

Baseline characteristics

Characteristic	DTG + RPV	Current Antiretroviral Regimen (CAR)	Total
Age, Continuous	43.3 Years STANDARD_DEVIATION 11.34	43.2 Years STANDARD_DEVIATION 9.64	43.3 Years STANDARD_DEVIATION 10.52
Race/Ethnicity, Customized African American/ African H. and White	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	11 Participants	7 Participants	18 Participants
Race/Ethnicity, Customized Black/African American	13 Participants	19 Participants	32 Participants
Race/Ethnicity, Customized Central/South Asian Heritage	0 Participants	1 Participants	1 Participants
Race/Ethnicity, Customized Japanese/East Asian (EA) Heritage (H.)/South EA H.	13 Participants	15 Participants	28 Participants
Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander	1 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized White	223 Participants	212 Participants	435 Participants
Sex: Female, Male Female	62 Participants	57 Participants	119 Participants
Sex: Female, Male Male	199 Participants	198 Participants	397 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	1 / 261	0 / 255	2 / 261	0 / 239	0 / 208	0 / 204
other Total, other adverse events	121 / 261	106 / 255	170 / 261	132 / 239	0 / 208	0 / 204
serious Total, serious adverse events	19 / 261	9 / 255	38 / 261	22 / 239	12 / 208	12 / 204

Outcome results

Primary

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior antiviral activity of switching to DTG+RPV once daily compared to continuation of CAR over 48 weeks in HIV-1 infected antiretroviral therapy (ART)-experienced participants. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

Time frame: Week 48

Population: The Analysis was performed on the Intent-to-Treat Exposed (ITT-E) population which consisted of all randomly assigned participants who received at least one dose of study drug.

Arm	Measure	Value (NUMBER)
DTG + RPV	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm	94 Percentage of participants
Current Antiretroviral Regimen (CAR)	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm	94 Percentage of participants

95% CI: [-3.9, 4.2]

Secondary

Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class

Blood samples were collected at Baseline (Day 1), Weeks 24 and 48 to assess fasting lipids which included total cholesterol (CHO), LDL cholesterol, HDL cholesterol and triglycerides. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 24 and 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 48, overall	-0.165 mmol/L	Standard Deviation 15.9301
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, Overall, Week 48	1.169 mmol/L	Standard Deviation 51.9844
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 24, overall	1.015 mmol/L	Standard Deviation 15.7472
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, Overall, Week 24	5.838 mmol/L	Standard Deviation 22.9614
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, Overall, Week 48	6.384 mmol/L	Standard Deviation 20.9244
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, Overall, Week 48	1.137 mmol/L	Standard Deviation 23.3849
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, Overall, Week 24	0.557 mmol/L	Standard Deviation 19.4929
DTG + RPV	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, Overall, Week 24	-0.825 mmol/L	Standard Deviation 42.5565
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 24, PI	0.936 mmol/L	Standard Deviation 11.853
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 48, PI	-1.971 mmol/L	Standard Deviation 12.2195
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, Overall, Week 48	4.723 mmol/L	Standard Deviation 18.3253
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, NNRTI, Week 24	-2.562 mmol/L	Standard Deviation 15.3521
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, NNRTI, Week 48	4.307 mmol/L	Standard Deviation 17.8013
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, INSTI, Week 24	-3.097 mmol/L	Standard Deviation 20.0002
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, INSTI, Week 48	5.386 mmol/L	Standard Deviation 20.6791
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, PI, Week 24	-2.031 mmol/L	Standard Deviation 15.9582
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, PI, Week 48	5.140 mmol/L	Standard Deviation 17.8779
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, Overall, Week 24	4.395 mmol/L	Standard Deviation 21.6685
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, Overall, Week 48	-0.598 mmol/L	Standard Deviation 20.6931
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, NNRTI, Week 24	5.959 mmol/L	Standard Deviation 21.5692
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, NNRTI, Week 48	0.747 mmol/L	Standard Deviation 19.2299
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, INSTI, Week 24	3.787 mmol/L	Standard Deviation 17.6755
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, INSTI, Week 48	2.647 mmol/L	Standard Deviation 24.043
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, PI, Week 24	0.983 mmol/L	Standard Deviation 24.5052
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	LDL CHO calculation, PI, Week 48	-6.212 mmol/L	Standard Deviation 20.4774
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, Overall, Week 24	9.379 mmol/L	Standard Deviation 45.5529
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, Overall, Week 48	7.183 mmol/L	Standard Deviation 44.7044
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, NNRTI, Week 24	4.962 mmol/L	Standard Deviation 40.6201
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, NNRTI, Week 48	5.248 mmol/L	Standard Deviation 41.7728
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, INSTI, Week 24	18.204 mmol/L	Standard Deviation 47.2348
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, PI, Week 24	13.241 mmol/L	Standard Deviation 54.2327
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, INSTI, Week 48	14.627 mmol/L	Standard Deviation 56.2824
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	Triglycerides, PI, Week 48	5.806 mmol/L	Standard Deviation 41.2106
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	HDL CHO direct, Overall, Week 24	-2.533 mmol/L	Standard Deviation 16.3641
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 24, overall	1.300 mmol/L	Standard Deviation 12.2269
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 48, overall	0.194 mmol/L	Standard Deviation 13.1071
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 24, NNRTI	1.238 mmol/L	Standard Deviation 12.4889
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 48, NNRTI	0.281 mmol/L	Standard Deviation 12.2469
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 24, INSTI	1.973 mmol/L	Standard Deviation 12.1365
Current Antiretroviral Regimen (CAR)	Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class	CHO, Week 48, INSTI	2.798 mmol/L	Standard Deviation 16.1468

Secondary

Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase

The Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in the participant and is the sum of the number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on the score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). Last observation carried forward (LOCF) was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 4, 24 and 48

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom count, Week 48	-0.5 Scores on a scale	Standard Deviation 4.33
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom Bother Score, Week 24	-1.8 Scores on a scale	Standard Deviation 8.4
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom count, Week 24	-0.7 Scores on a scale	Standard Deviation 4.31
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom Bother Score, Week 48	-1.5 Scores on a scale	Standard Deviation 7.97
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom Bother Score, Week 4	-2.8 Scores on a scale	Standard Deviation 7.44
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom count, Week 4	-1.1 Scores on a scale	Standard Deviation 4.11
Current Antiretroviral Regimen (CAR)	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom Bother Score, Week 4	-1.8 Scores on a scale	Standard Deviation 7.24
Current Antiretroviral Regimen (CAR)	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom count, Week 24	-0.8 Scores on a scale	Standard Deviation 4.64
Current Antiretroviral Regimen (CAR)	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom count, Week 48	-0.4 Scores on a scale	Standard Deviation 4.82
Current Antiretroviral Regimen (CAR)	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom count, Week 4	-0.8 Scores on a scale	Standard Deviation 4.02
Current Antiretroviral Regimen (CAR)	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom Bother Score, Week 24	-1.7 Scores on a scale	Standard Deviation 8.72
Current Antiretroviral Regimen (CAR)	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase	Symptom Bother Score, Week 48	-0.7 Scores on a scale	Standard Deviation 9.3

p-value: 0.43ANCOVA

p-value: 0.03995% CI: [-2.414, -0.064]ANCOVA

p-value: 0.542ANCOVA

p-value: 0.44895% CI: [-1.896, 0.84]ANCOVA

p-value: 0.402ANCOVA

p-value: 0.16495% CI: [-2.501, 0.426]ANCOVA

Secondary

Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

The Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in the participant and is the sum of the number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on the score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). LOCF was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 56, 76, 100 and 148

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom count, Week 56	-0.8 Scores on a scale	Standard Deviation 4.8
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom count, Week 76	-0.6 Scores on a scale	Standard Deviation 4.66
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom count, Week 100	-0.5 Scores on a scale	Standard Deviation 5.03
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom count, Week 148	-0.7 Scores on a scale	Standard Deviation 4.87
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom Bother Score, Week 56	-1.8 Scores on a scale	Standard Deviation 9.23
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom Bother Score, Week 76	-1.6 Scores on a scale	Standard Deviation 8.7
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom Bother Score, Week 100	-1.4 Scores on a scale	Standard Deviation 9.4
DTG + RPV	Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Symptom Bother Score, Week 148	-1.7 Scores on a scale	Standard Deviation 9.54

Secondary

Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase

The HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 to 6 where a higher score indicates the greater improvement in the past few weeks. These items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscales: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). The HIV TSQ was administered as a paper questionnaire. Total score, lifestyle/ease score and General satisfaction/clinical sub-score (CS) have been summarized. LOCF was used as primary method of analysis. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 4, 24 and 48

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEDIAN)
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	Total score, Week 24	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	lifestyle/ease Sub-score, Week 48	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	lifestyle/ease Sub-score, Week 4	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	General Satisfaction/CS, Week 4	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	Total score, Week 48	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	General Satisfaction/CS, Week 24	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	lifestyle/ease Sub-score, Week 24	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	General Satisfaction/CS, Week 48	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	Total score, Week 4	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	General Satisfaction/CS, Week 48	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	Total score, Week 4	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	Total score, Week 24	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	Total score, Week 48	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	lifestyle/ease Sub-score, Week 4	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	lifestyle/ease Sub-score, Week 24	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	lifestyle/ease Sub-score, Week 48	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	General Satisfaction/CS, Week 4	0.0 Score on a scale
Current Antiretroviral Regimen (CAR)	Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase	General Satisfaction/CS, Week 24	0.0 Score on a scale

p-value: 0.037Wilcoxon rank sum test

p-value: 0.101Wilcoxon rank sum test

p-value: 0.042Wilcoxon rank sum test

p-value: 0.132Wilcoxon rank sum test

p-value: 0.022Wilcoxon rank sum test

p-value: 0.004Wilcoxon rank sum test

p-value: 0.076Wilcoxon rank sum test

p-value: 0.073Wilcoxon rank sum test

p-value: 0.547Wilcoxon rank sum test

Secondary

Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

The HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Change from Baseline is calculated as the value at specified time point minus Baseline value. Total score, lifestyle/ease score and General satisfaction/clinical sub-score (CS) have been summarized. LOCF was used as primary method of analysis.

Time frame: At Weeks 56, 76, 100 and 148

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEDIAN)
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Total score, Week 56	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Total score, Week 76	1.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Total score, Week 100	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Total score, Week 148	1.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	lifestyle/ease Sub-score, Week 56	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	lifestyle/ease Sub-score, Week 76	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	lifestyle/ease Sub-score, Week 100	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	lifestyle/ease Sub-score, Week 148	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	General Satisfaction/CS, Week 56	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	General Satisfaction/CS, Week 76	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	General Satisfaction/CS, Week 100	0.0 Score on a scale
DTG + RPV	Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	General Satisfaction/CS, Week 148	0.0 Score on a scale

Secondary

Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase

The Symptom Distress Module, also called the HIV Symptom Index or Symptoms Impact Questionnaire, is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Symptom count is based on which of the 20 symptoms were present in the participant and is the sum of the number of symptoms present and ranges from 0 (none) to 20 (all). Symptom bother score is based on the score for each symptom present ranging from 1 (it doesn't bother me) to 4 (it bothers me a lot). Symptom bother score is the unweighted sum of the bother item scores for each symptom. The symptom bother score ranges from 0 (minimum bother score) to 80 (maximum bother score). LOCF was used as primary method of analysis. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value.

Time frame: At Weeks 56, 76, 100 and 148

Population: LS ITT-E Population comprised of all participants randomized to CAR who received at least one dose of study treatment at or after the Week 52 Switch visit. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom Bother Score, Week 100	-0.8 Scores on a scale	Standard Deviation 8.43
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom count, Week 56	-0.9 Scores on a scale	Standard Deviation 4.74
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom count, Week 76	-0.7 Scores on a scale	Standard Deviation 4.29
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom count, Week 100	-0.4 Scores on a scale	Standard Deviation 5.04
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom count, Week 148	-0.6 Scores on a scale	Standard Deviation 4.81
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom Bother Score, Week 56	-2.1 Scores on a scale	Standard Deviation 7.56
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom Bother Score, Week 76	-1.0 Scores on a scale	Standard Deviation 7.61
DTG + RPV	Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Symptom Bother Score, Week 148	-1.0 Scores on a scale	Standard Deviation 8.54

Secondary

Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase

The HIV TSQ is a 10-item self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience, flexibility. Each item is scored 0 (very dissatisfied, inconvenient) to 6 (very satisfied, convenient). The items are summed up to produce a treatment satisfaction total score (0 to 60) and 2 subscale scores: general satisfaction/clinical and lifestyle/ease subscales (0 to 30). Higher scores indicated greater treatment satisfaction as compared to the past few weeks. The HIV TSQ was administered as a paper questionnaire. Change from LS Baseline is calculated as the value at specified time point minus LS Baseline value. Total score, lifestyle/ease score and General satisfaction/CS have been summarized. LOCF was used as primary method of analysis.

Time frame: At Weeks 56, 76, 100 and 148

Population: LS ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEDIAN)
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Total score, Week 56	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Total score, Week 76	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Total score, Week 100	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	Total score, Week 148	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	lifestyle/ease Sub-score, Week 56	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	lifestyle/ease Sub-score, Week 76	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	lifestyle/ease Sub-score, Week 100	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	lifestyle/ease Sub-score, Week 148	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	General Satisfaction/CS, Week 56	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	General Satisfaction/CS, Week 76	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	General Satisfaction/CS, Week 100	0.0 Score on a scale
DTG + RPV	Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase	General Satisfaction/CS, Week 148	0.0 Score on a scale

Secondary

Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class

Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out at Baseline (Day 1) and Week 48 to assess the impact of Baseline third agent class (INSTI, NNRTI, or PI) on efficacy, safety and tolerability of DTG +RPV compared to continuation of CAR. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	PI	10.5 Cells per mm^3	Standard Deviation 163.67
DTG + RPV	Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	NNRTI	49.7 Cells per mm^3	Standard Deviation 166.4
DTG + RPV	Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	INSTI	-11.2 Cells per mm^3	Standard Deviation 176.56
Current Antiretroviral Regimen (CAR)	Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	NNRTI	24.3 Cells per mm^3	Standard Deviation 160.32
Current Antiretroviral Regimen (CAR)	Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	INSTI	10.3 Cells per mm^3	Standard Deviation 155.53
Current Antiretroviral Regimen (CAR)	Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class	PI	12.2 Cells per mm^3	Standard Deviation 163.32

Secondary

Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48

Blood samples were collected and CD4+ cell count assessment by flow cytometry was carried out to evaluate the immunological activity of DTG + RPV once daily compared to continuation of CAR. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 24 and 48

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48	Week 24	42.0 Cells per millimeter cube (mm^3)	Standard Deviation 172.29
DTG + RPV	Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48	Week 48	28.0 Cells per millimeter cube (mm^3)	Standard Deviation 169.35
Current Antiretroviral Regimen (CAR)	Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48	Week 24	42.4 Cells per millimeter cube (mm^3)	Standard Deviation 164.85
Current Antiretroviral Regimen (CAR)	Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48	Week 48	18.4 Cells per millimeter cube (mm^3)	Standard Deviation 159.34

Secondary

Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess B2M and 25 hydroxy-vitamin D. Urine biomarker samples were collected to assess B2M and RBP. Change from Baseline was calculated as value at indicated time point minus Baseline value. For 25 hydroxy-vitamin D, analysis of changes from Baseline was performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	B2M, blood	-16.8800 Nanomoles (nmol)/L	Standard Deviation 34.8933
DTG + RPV	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	25 hydroxy-vitamin D, blood	-13.9 Nanomoles (nmol)/L	Standard Deviation 25.3
DTG + RPV	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	Urine B2M	-173.2820 Nanomoles (nmol)/L	Standard Deviation 1311.24142
DTG + RPV	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	Urine RBP	-6.8123 Nanomoles (nmol)/L	Standard Deviation 24.0965
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	Urine RBP	-0.0631 Nanomoles (nmol)/L	Standard Deviation 11.99886
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	B2M, blood	-4.7501 Nanomoles (nmol)/L	Standard Deviation 43.04355
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	Urine B2M	62.3209 Nanomoles (nmol)/L	Standard Deviation 391.32049
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48	25 hydroxy-vitamin D, blood	-9.2 Nanomoles (nmol)/L	Standard Deviation 19.55

p-value: 0.007ANCOVA

p-value: 0.01195% CI: [0.767, 0.967]ANCOVA

p-value: 0.74595% CI: [0.943, 1.085]ANCOVA

p-value: 0.01895% CI: [0.787, 0.977]ANCOVA

Secondary

Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess bone-specific alkaline phosphatase, procollagen 1 N-terminal propeptide, osteocalcin, Type 1 Collagen C-telopeptides and sVCAM. Change from Baseline was calculated as value at indicated time point minus Baseline value. For bone-specific alkaline phosphatase, procollagen 1-N-propeptide, osteocalcin and type 1 collagen C-telopeptide, analyses of changes from Baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Procollagen type 1 N-propeptide	-5.8 Microgram (ug)/L	Standard Deviation 20
DTG + RPV	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Type I Collagen C-Telopeptides	-0.15 Microgram (ug)/L	Standard Deviation 0.313
DTG + RPV	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Osteocalcin	-5.11 Microgram (ug)/L	Standard Deviation 7.334
DTG + RPV	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	sVCAM	-2.63 Microgram (ug)/L	Standard Deviation 571.182
DTG + RPV	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Bone-specific alkaline phosphatase	-3.18 Microgram (ug)/L	Standard Deviation 5.678
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	sVCAM	37.42 Microgram (ug)/L	Standard Deviation 617.486
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Bone-specific alkaline phosphatase	0.92 Microgram (ug)/L	Standard Deviation 4.634
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Procollagen type 1 N-propeptide	0.3 Microgram (ug)/L	Standard Deviation 19.28
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Osteocalcin	-1.14 Microgram (ug)/L	Standard Deviation 6.017
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48	Type I Collagen C-Telopeptides	-0.09 Microgram (ug)/L	Standard Deviation 0.344

p-value: 0.001ANCOVA

p-value: <0.00195% CI: [0.686, 0.773]ANCOVA

p-value: 0.00495% CI: [0.785, 0.954]ANCOVA

p-value: <0.00195% CI: [0.719, 0.864]ANCOVA

p-value: 0.677ANCOVA

p-value: <0.00195% CI: [0.823, 0.914]ANCOVA

p-value: <0.001ANCOVA

p-value: <0.00195% CI: [0.799, 0.91]ANCOVA

p-value: 0.02895% CI: [0.796, 0.987]ANCOVA

p-value: <0.00195% CI: [0.672, 0.822]ANCOVA

p-value: 0.782ANCOVA

p-value: <0.00195% CI: [0.751, 0.891]ANCOVA

Secondary

Mean Change From Baseline in Cystatin C at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess cystatin C. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Cystatin C at Week 48	-0.02 mg/L	Standard Deviation 0.11
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Cystatin C at Week 48	-0.01 mg/L	Standard Deviation 0.108

Secondary

Mean Change From Baseline in D-Dimer at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess D-Dimer. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in D-Dimer at Week 48	0.01 Nanomole/L fibrinogen equivalent units	Standard Deviation 1.629
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in D-Dimer at Week 48	-0.13 Nanomole/L fibrinogen equivalent units	Standard Deviation 2.932

Secondary

Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48

Blood samples were collected at Baseline (Day 1), Week 24 and Week 48 to assess fasting lipids which included total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 24 and 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Total cholesterol, Week 24	-0.015 Millimoles (mmol)/L	Standard Deviation 0.7539
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Total cholesterol, Week 48	-0.079 Millimoles (mmol)/L	Standard Deviation 0.7926
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	LDL cholesterol calculation, Week 24	0.085 Millimoles (mmol)/L	Standard Deviation 0.594
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	LDL cholesterol calculation, Week 48	-0.049 Millimoles (mmol)/L	Standard Deviation 0.6276
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	HDL cholesterol direct, Week 24	-0.024 Millimoles (mmol)/L	Standard Deviation 0.2365
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	HDL cholesterol direct, Week 48	0.051 Millimoles (mmol)/L	Standard Deviation 0.2386
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Triglycerides, Week 24	-0.184 Millimoles (mmol)/L	Standard Deviation 1.0102
DTG + RPV	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Triglycerides, Week 48	-0.169 Millimoles (mmol)/L	Standard Deviation 1.0062
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Triglycerides, Week 48	-0.021 Millimoles (mmol)/L	Standard Deviation 1.0156
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Total cholesterol, Week 24	0.020 Millimoles (mmol)/L	Standard Deviation 0.5777
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	HDL cholesterol direct, Week 24	-0.051 Millimoles (mmol)/L	Standard Deviation 0.2258
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Total cholesterol, Week 48	-0.038 Millimoles (mmol)/L	Standard Deviation 0.6148
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	Triglycerides, Week 24	0.040 Millimoles (mmol)/L	Standard Deviation 0.9164
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	LDL cholesterol calculation, Week 24	0.055 Millimoles (mmol)/L	Standard Deviation 0.5232
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	HDL cholesterol direct, Week 48	0.049 Millimoles (mmol)/L	Standard Deviation 0.2489
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48	LDL cholesterol calculation, Week 48	-0.076 Millimoles (mmol)/L	Standard Deviation 0.528

Secondary

Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess FABP and soluble CD14. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48	FABP	-1.50 Nanogram/milliliter	Standard Deviation 1.278
DTG + RPV	Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48	Soluble CD14	456.69 Nanogram/milliliter	Standard Deviation 731.833
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48	FABP	-0.99 Nanogram/milliliter	Standard Deviation 1.441
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48	Soluble CD14	802.26 Nanogram/milliliter	Standard Deviation 878.304

Secondary

Mean Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess hs-CRP. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 48	0.10 mg/Liter (L)	Standard Deviation 5.383
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 48	0.80 mg/Liter (L)	Standard Deviation 8.527

Secondary

Mean Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess insulin resistance. Change from Baseline was calculated as value at indicated time point minus Baseline value. The homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR ) index , the product of basal glucose and insulin levels divided by 22.5, is regarded as a simple, inexpensive, and reliable surrogate measure of insulin resistance.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Week 48	0.50 HOMA-IR Score	Standard Deviation 4.78
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Week 48	0.80 HOMA-IR Score	Standard Deviation 3.938

Secondary

Mean Change From Baseline in Interleukin 6 (IL-6) at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess IL-6. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Interleukin 6 (IL-6) at Week 48	-0.08 Nanograms (ng)/L	Standard Deviation 2.373
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Interleukin 6 (IL-6) at Week 48	-0.07 Nanograms (ng)/L	Standard Deviation 2.761

Secondary

Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess RBP, serum creatinine and glucose. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	RBP	-0.13 mg/deciliter (dL)	Standard Deviation 0.825
DTG + RPV	Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	Serum creatinine	0.100 mg/deciliter (dL)	Standard Deviation 0.1053
DTG + RPV	Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	Glucose	0.187 mg/deciliter (dL)	Standard Deviation 19.5808
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	RBP	0.00 mg/deciliter (dL)	Standard Deviation 0.872
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	Serum creatinine	-0.003 mg/deciliter (dL)	Standard Deviation 0.0847
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48	Glucose	3.220 mg/deciliter (dL)	Standard Deviation 10.0987

Secondary

Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48

Blood biomarker samples were collected at Baseline (Day 1) and Week 48 to assess soluble CD163 and oxidized LDL. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48	Soluble CD163	65.38 Microgram(µg)/Liter	Standard Deviation 180.869
DTG + RPV	Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48	Oxidized LDL	60.87 Microgram(µg)/Liter	Standard Deviation 504.345
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48	Soluble CD163	53.94 Microgram(µg)/Liter	Standard Deviation 215.621
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48	Oxidized LDL	13.92 Microgram(µg)/Liter	Standard Deviation 575.305

Secondary

Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48

Urine biomarker samples were collected at Baseline (Day 1) and Week 48 to assess urine albumin/creatinine ratio and urine protein/creatinine ratio. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48	Urine albumin/creatinine ratio	-0.78 Grams (g)/mol	Standard Deviation 5.116
DTG + RPV	Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48	Urine protein/creatinine ratio	-2.73 Grams (g)/mol	Standard Deviation 12.683
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48	Urine albumin/creatinine ratio	-0.64 Grams (g)/mol	Standard Deviation 9.538
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48	Urine protein/creatinine ratio	1.23 Grams (g)/mol	Standard Deviation 5.088

Secondary

Mean Change From Baseline in Urine Phosphate at Week 48

Urine biomarker samples were collected to at Baseline (Day 1) and Week 48 to assess urine phosphate. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Week 48

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
DTG + RPV	Mean Change From Baseline in Urine Phosphate at Week 48	1.335 Millimoles (mmol)/L	Standard Deviation 16.7211
Current Antiretroviral Regimen (CAR)	Mean Change From Baseline in Urine Phosphate at Week 48	-0.798 Millimoles (mmol)/L	Standard Deviation 15.3771

Secondary

Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any AE, AELD or AE with maximum grade toxicity experienced by any one participant over 48 weeks by Baseline third agent class (INSTI, NNRTI, or PI) is summarized. AEs were graded using the Division of AIDS grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening.

Time frame: Up to 48 weeks

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Any AE, NNRTI	106 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Any AE, INSTI	47 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Any AE, PI	42 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 1 AE	68 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 2 AE	30 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 3 AE	8 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 4 AE	0 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 1 AE	27 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 2 AE	15 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 3 AE	5 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 4 AE	0 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 1 AE	24 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 2 AE	14 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 3 AE	3 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 4 AE	1 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	AELD, NNRTI	5 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	AELD, INSTI	4 Participants
DTG + RPV	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	AELD, PI	3 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 3 AE	3 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Any AE, NNRTI	96 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 3 AE	1 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Any AE, INSTI	36 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	AELD, PI	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	Any AE, PI	42 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 4 AE	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 1 AE	76 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 4 AE	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 2 AE	19 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 1 AE	26 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 3 AE	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	AELD, INSTI	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Maximum toxicity Grade 4 AE	1 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Maximum toxicity Grade 2 AE	13 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 1 AE	20 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	AELD, NNRTI	1 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Maximum toxicity Grade 2 AE	15 Participants

Secondary

Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with use of a medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE. AEs were graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading. Grade 1=mild; Grade 2=moderate, Grade 3=severe and Grade 4=potentially life-threatening. Common AEs were those with \>5% incidence for either treatment.

Time frame: Up to Week 410 or study discontinuation

Population: Safety Population included all randomized participants who received at least one dose of study drug.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 1 AE	78 Participants
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 3 AE	33 Participants
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Any SAE	50 Participants
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 4 AE	13 Participants
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 2 AE	104 Participants
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	AELD	23 Participants
DTG + RPV	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Common non-serious AE	166 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	AELD	8 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Common non-serious AE	132 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Any SAE	32 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 1 AE	85 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 2 AE	95 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 3 AE	29 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)	Maximum toxicity Grade 4 AE	11 Participants

Secondary

Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase

Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW Criteria has been presented.

Time frame: Post-Late switch (LS) Baseline (Week 52) up to Week 148

Population: The analysis was performed on the Late Switch (LS) CVW resistance Population which was comprised of all participants in the LS ITT-E Population who met CVW through the end of visit window (Week 48, Week 100 or Week 148) and had available on-treatment genotypic resistance data at the time CVW criterion is met. Only those participants with data available at the specified time point were analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, DTG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, EVG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, EVG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, EVG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, EVG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, EVG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, RAL, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, RAL, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, RAL, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, RAL, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	INI, RAL, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, DLV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, DLV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, DLV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, DLV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, DLV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, EFV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, EFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, EFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, EFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, EFV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, ETR, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, ETR, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, ETR, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, ETR, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, ETR, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, NVP, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, NVP, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, NVP, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, NVP, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, NVP, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, RPV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NNRTI, RPV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, 3TC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, 3TC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, 3TC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, 3TC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, 3TC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ABC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ABC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ABC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ABC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ABC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, FTC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, FTC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, FTC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, FTC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, FTC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, TDF, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, TDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, TDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, TDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, TDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ZDV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ZDV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ZDV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ZDV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ZDV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, d4T, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, d4T, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, d4T, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, d4T, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, d4T, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ddI, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ddI, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ddI, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ddI, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	NRTI, ddI, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, ATV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, ATV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, ATV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, ATV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, ATV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, DRV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, DRV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, DRV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, DRV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, DRV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, FPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, FPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, FPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, FPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, FPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, IDV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, IDV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, IDV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, IDV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, IDV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, LPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, LPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, LPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, LPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, LPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, NFV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, NFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, NFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, NFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, NFV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, RTV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, RTV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, RTV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, RTV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, RTV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, SQV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, SQV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, SQV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, SQV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, SQV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, TPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, TPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, TPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, TPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase	PI, TPV/r, High-level resistance	0 Participants

Secondary

Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase

Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential phenotypic evolution of resistance. Phenotypic Resistance data for the following drugs was presented: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.

Time frame: Week 52 to Week 410

Population: The analysis was performed on the Late Switch CVW resistance population which included all participants from the Late Switch ITT-E population who met CVW through the end of visit window and had available on-treatment genotypic resistance data at the time the CVW criterion was met.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, DTG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, EVG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, EVG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, EVG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, EVG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, EVG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, RAL, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, RAL, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, RAL, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, RAL, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	INI, RAL, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, DLV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, DLV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, DLV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, DLV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, DLV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, EFV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, EFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, EFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, EFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, EFV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, ETR, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, ETR, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, ETR, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, ETR, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, ETR, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, NVP, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, NVP, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, NVP, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, NVP, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, NVP, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, RPV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NNRTI, RPV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, 3TC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, 3TC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, 3TC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, 3TC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, 3TC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ABC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ABC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ABC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ABC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ABC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, FTC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, FTC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, FTC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, FTC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, FTC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, TDF, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, TDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, TDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, TDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, TDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ZDV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ZDV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ZDV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ZDV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ZDV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, d4T, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, d4T, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, d4T, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, d4T, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, d4T, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ddI, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ddI, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ddI, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ddI, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	NRTI, ddI, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, ATV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, ATV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, ATV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, ATV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, ATV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, DRV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, DRV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, DRV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, DRV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, DRV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, FPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, FPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, FPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, FPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, FPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, IDV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, IDV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, IDV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, IDV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, IDV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, LPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, LPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, LPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, LPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, LPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, NFV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, NFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, NFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, NFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, NFV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, RTV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, RTV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, RTV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, RTV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, RTV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, SQV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, SQV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, SQV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, SQV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, SQV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, TPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, TPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, TPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, TPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase	PI, TPV/r, High-level resistance	0 Participants

Secondary

Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase

Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (DTG, Elvitegravir \[EVG\], Raltegravir \[RAL\], Delavirdine \[DLV\], Efavirenz \[EFV\], Etravirine \[ETR\], Nevirapine \[NVP\], RPV, Lamivudine \[3TC\], Abacavir \[ABC\], FTC, TDF, Zidovudine \[ZDV\], Stavudine \[d4T\], Didanosine \[ddI\], Atazanavir/r \[ATV/r\], DRV/r, Fosamprenavir/r \[FPV/r\], Indinavir/r \[IDV/r\], Lopinavir/r \[LPV/r\], Nelfinavir \[NFV\], Ritonavir \[RTV\], Saquinavir/r \[SQV/r\], Tipranavir/r \[TPV/r\]) in participants Meeting Confirmed Virologic Withdrawal Criteria has been presented.

Time frame: Up to Week 148

Population: CVW resistance Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, RTV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, DTG, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, EVG, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, EVG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, EVG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, EVG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, EVG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, RAL, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, RAL, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, RAL, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, RAL, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	INI, RAL, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, DLV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, DLV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, DLV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, DLV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, DLV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, EFV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, EFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, ETR, Low-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, EFV, Low-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, EFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, EFV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, ETR, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, ETR, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, ETR, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, ETR, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, NVP, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, NVP, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, NVP, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, NVP, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, NVP, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, RPV, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NNRTI, RPV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, 3TC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, 3TC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, 3TC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, 3TC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, 3TC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ABC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ABC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ABC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ABC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ABC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, FTC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, FTC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, FTC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, FTC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, FTC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, TDF, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, TDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, TDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, TDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, TDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ZDV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ZDV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ZDV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ZDV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ZDV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, d4T, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, d4T, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, d4T, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, d4T, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, d4T, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ddI, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ddI, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ddI, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ddI, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	NRTI, ddI, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, ATV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, ATV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, ATV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, ATV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, ATV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, DRV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, DRV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, DRV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, DRV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, DRV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, FPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, FPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, FPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, FPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, FPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, IDV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, IDV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, IDV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, IDV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, IDV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, LPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, LPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, LPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, LPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, LPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, NFV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, NFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, NFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, NFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, NFV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, RTV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, RTV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, RTV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, RTV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, SQV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, SQV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, SQV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, SQV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, SQV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, TPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, TPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, TPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, TPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase	PI, TPV/r, High-level resistance	0 Participants

Secondary

Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase

Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential genotypic evolution of resistance. Genotypic Resistance data for the following drugs was presented: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.

Time frame: Up to Week 410

Population: The analysis was performed on the CVW Resistance population which included all participants from the Intent-to-Treat Exposed (ITT-E) population who met CVW through the end of the visit window and had available on-treatment genotypic resistance data at the time the CVW criterion was met.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Low-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Low-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, High-level resistance	0 Participants

Secondary

Number of Participants With Genotypic Resistance-Early Switch Phase

Plasma samples were collected for drug resistance testing. Genotypic Resistance data for the following drugs (Rilpivirine \[RPV\], Dolutegravir \[DTG\]) in participants Meeting Confirmed Virologic Withdrawal (CVW) criteria has been presented.

Time frame: Up to Week 48

Population: The analysis was performed on the CVW resistance Population which was comprised of all participants in the ITT-E Population who met CVW through the end of visit window (Week 48, Week 100 or Week 148) and have available on-treatment genotypic resistance data at the time CVW criterion is met.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	INSTI, DTG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	INSTI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	INSTI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	INSTI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	INSTI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	NNRTI, RPV, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Genotypic Resistance-Early Switch Phase	NNRTI, RPV, High-level resistance	0 Participants

Secondary

Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks

Blood samples were collected to evaluate alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, glucose, potassium, phosphate, sodium, blood urea nitrogen (BUN), total carbon dioxide, lipase, creatine phosphokinase and creatinine clearance. Value obtained at Day 1 was considered as Baseline value. Number of participants who experienced maximum grade toxicity post-baseline in clinical chemistry over 48 weeks was summarized. Clinical chemistry toxicities were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; Grade 2=moderate, Grade 3=severe and Grade 4=potentially life-threatening. For all laboratory parameters, one assessment out of range was sufficient to be considered a chemistry toxicity.

Time frame: Up to 48 weeks

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 1	92 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 2	72 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 3	11 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 4	1 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 4	10 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 1	80 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 3	16 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks	Grade 2	79 Participants

Secondary

Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class

Blood samples were collected at Baseline (Day 1) and at Weeks 4, 8, 12, 24, 36 and 48 to evaluate ALT, albumin, ALP, AST, total bilirubin, chloride, creatinine, glucose, potassium, phosphate, sodium, BUN, total carbon dioxide, lipase, creatine phosphokinase and creatinine clearance. Number of participants who experienced maximum toxicity grade post-baseline in chemistry parameters over 48 weeks by Baseline third agent treatment class (INSTI, NNRTI, PI) is summarized. Clinical chemistry toxicities were graded using the DAIDS grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening.

Time frame: Up to 48 weeks

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 1	51 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 2	31 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 3	7 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 4	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 1	19 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 2	23 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 3	3 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 4	0 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 1	22 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 2	18 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 3	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 4	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 3	9 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 1	52 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 3	3 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 2	40 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 2	21 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 3	4 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 4	2 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI, Grade 4	5 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 4	3 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 1	11 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI, Grade 1	17 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INSTI, Grade 2	18 Participants

Secondary

Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks

Blood samples were collected to evaluate hemoglobin, hematocrit, basophils, eosinophils, lymphocytes, monocytes, neutrophils, mean corpuscular volume (MCV), red blood cell (RBC) count, white blood cell (WBC) count and platelet count. Value obtained at Day 1 was considered as Baseline value. Number of participants who experienced maximum grade toxicity post-baseline in hematology over 48 weeks was summarized. Hematology toxicities were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; Grade 2=moderate, Grade 3=severe and Grade 4=potentially life-threatening. For all laboratory parameters, one assessment out of range was sufficient to be considered a hematology toxicity.

Time frame: Up to 48 weeks

Population: Safety Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 1	11 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 2	2 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 3	3 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 4	1 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 4	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 1	11 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 3	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks	Grade 2	2 Participants

Secondary

Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class

Blood samples were collected at Baseline (Day 1) and at Weeks 4, 8, 12, 24, 36 and 48 to evaluate hemoglobin, hematocrit, basophils, eosinophils, lymphocytes, monocytes, neutrophils, MCV, RBC count, WBC count and platelet count. Number of participants who experienced maximum toxicity grade post-baseline in hematology parameters over 48 weeks by Baseline third agent treatment class (INSTI, NNRTI, PI) was summarized. Hematology toxicities were graded using the DAIDS grading. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening.

Time frame: Up to 48 weeks

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 1	7 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 2	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 3	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 4	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 1	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 2	0 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 3	0 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 4	0 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 1	3 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 2	1 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 3	2 Participants
DTG + RPV	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 4	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 3	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 1	6 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 3	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 2	2 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 2	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 3	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 4	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	NNRTI; Grade 4	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 4	0 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 1	1 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	PI; Grade 1	4 Participants
Current Antiretroviral Regimen (CAR)	Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class	INI; Grade 2	0 Participants

Secondary

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class

For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were to be analyzed in an attempt to obtain genotype data on as many samples as possible. Samples for drug resistance testing (genotypic) were to be collected at Day 1. Number of participants with genotypic resistance to CAR and to DTG or RPV for those meeting virologic withdrawal criteria in subgroups stratified based on Baseline third agent treatment class (INSTI, NNRTI, PI) were to be summarized.

Time frame: Week 48

Population: CVW resistance Population. This outcome has not been analyzed as the number of participants was low (1 CVW per arm) and summaries by Baseline third agent were not provided. Therefore, data are not available for this outcome measure due to the insufficient number of participants with events.

Secondary

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase

For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain genotype data on as many samples as possible. Number of participants with genotypic resistance to CAR for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.

Time frame: Week 52 to Week 410

Population: The analysis was performed on the Late Switch CVW Resistance population.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, DTG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, EVG, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, EVG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, EVG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, EVG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, EVG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, RAL, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, RAL, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, RAL, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, RAL, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, INI, RAL, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, NFV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, NFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, NFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, NFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, NFV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, RTV, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, RTV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, RTV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, RTV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, RTV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, NCP, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Susceptible	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, High-level resistance	0 Participants

Secondary

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase

For all participants who met virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain genotype data on as many samples as possible. Samples for drug resistance testing (genotypic) were collected at Day 1. Number of participants with genotypic resistance to DTG or RPV for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.

Time frame: Up to Week 410

Population: The analysis was performed on the CVW Resistance population.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Low-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Low-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVF, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVF, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVF, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Intermediate resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, High-level resistance	1 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Susceptible	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, High-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Susceptible	2 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Potential low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Low-level resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Intermediate resistance	0 Participants
DTG + RPV	Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, High-level resistance	0 Participants

Secondary

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class

For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were to be analyzed in an attempt to obtain phenotype data on as many samples as possible. Samples for drug resistance testing (phenotypic) were to be collected at Day 1. Number of participants with phenotypic resistance to CAR and to DTG or RPV for those meeting virologic withdrawal criteria in subgroups stratified based on Baseline third agent treatment class (INSTI, NNRTI, PI) were to be summarized.

Time frame: Week 48

Population: CVW resistance Population. This outcome was not analyzed as the number of participants was low (1 CVW per arm) and summaries by Baseline third agent were not provided. Therefore, data are not available for this outcome measure due to the insufficient number of participants with events.

Secondary

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase

For all participants who meet virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain phenotype data on as many samples as possible. Number of participants with phenotypic resistance to CAR for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.

Time frame: Week 52 to Week 410

Population: The analysis was performed on the Late Switch CVW resistance population.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, DLV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, EFV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Partially Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, ETR, Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, NVP, Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NNRTI, RPV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Reistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, 3TC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ABC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, FTC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, TDF, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ZDF, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, d4T, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, NRTI, ddI, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, ATV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, DRV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, FPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, IDV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, LPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, NFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, NFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, RTV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, RTV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Partiallly Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, SQV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase	NNRTI, PI, TPV/r, Sensitive	1 Participants

Secondary

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase

For all participants who met virologic withdrawal criteria, plasma samples with HIV-1 RNA level \>=200 c/mL were analyzed in an attempt to obtain phenotype data on as many samples as possible. Samples for drug resistance testing (phenotypic) were collected at Day 1. Number of participants with phenotypic resistance to DTG or RPV for those meeting virologic withdrawal criteria in subgroups, stratified based on baseline third agent treatment class (NNRTI) were summarized.

Time frame: Up to Week 410

Population: The analysis was performed on the CVW Resistance population.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, DTG, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, EVG, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, INI, RAL, Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, DLV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, EFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, ETR, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVP, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVP, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, NVP, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Resistant	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NNRTI, RPV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Reistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, 3TC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ABC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, FTC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, TDF, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ZDF, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, d4T, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ddI, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, NRTI, ddI, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, ATV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, DRV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, FPV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, IDV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, yResistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, LPV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, NFV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, RTV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Partiallly Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, SQV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase	NNRTI, PI, TPV/r, Sensitive	2 Participants

Secondary

Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase

Plasma samples were collected for participants meeting the CVW criteria (previous plasma HIV-1 RNA \>=50 c/mL and current plasma HIV-1 RNA \>= 200 c/mL) to evaluate any potential phenotypic evolution of resistance. Phenotypic resistance data for the following drugs was presented: DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r.

Time frame: Week 52 to Week 410

Population: The analysis was performed on the Late Switch CVW Resistance population which included all participants from the Late Switch ITT-E population who met CVW through the end of visit window and had available on-treatment phenotypic resistance data at the time the CVW criterion was met.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, DLV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, DLV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, DLV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, EFV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, EFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, EFV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, ETR, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, ETR, Partially Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, ETR, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, NVP, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, NVP, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, NVP, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, RPV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, RPV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NNRTI, RPV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, 3TC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, 3TC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, 3TC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ABC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ABC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, FTC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, FTC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, TDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, TDF, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ZDV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ZDV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ZDV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, d4T, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, d4T, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ddI, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	NRTI, ddI, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, ATV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, ATV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, DRV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, DRV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, FPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, FPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, IDV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, IDV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, LPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, LPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, LPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, NFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, NFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, RTV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, RTV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, SQV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, SQV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, TPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase	PI, TPV/r, Sensitive	1 Participants

Secondary

Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase

Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, NFV, RTV, SQV/r, TPV/r) in participants Meeting CVW criteria has been presented.

Time frame: Post-LS Baseline (Week 52) up to Week 148

Population: LS CVW resistance Population

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ddI, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, FTC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, DLV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, DLV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, DLV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, EFV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, EFV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, EFV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, ETR, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, ETR, Partially sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, ETR, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, NVP, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, NVP, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, NVP, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, RPV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, RPV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NNRTI, RPV, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, 3TC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, 3TC, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, 3TC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ABC, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ABC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, FTC, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, TDF, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, TDF, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ZDV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ZDV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ZDV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, d4T, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, d4T, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	NRTI, ddI, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, ATV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, ATV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, DRV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, DRV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, FPV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, FPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, IDV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, IDV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, LPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, LPV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, LPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, NFV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, NFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, RTV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, RTV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, SQV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, SQV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, TPV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase	PI, TPV/r, Sensitive	1 Participants

Secondary

Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase

Time frame: Up to Week 410

Population: The analysis was performed on the CVW Resistance population which included all participants from the ITT-E population who met CVW through the end of the visit window and had available on-treatment phenotypic resistance data at the time the CVW criterion was met.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, EFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, ETR, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, NVP, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, RPV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, 3TC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ABC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, FTC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, TDF, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ZDV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, IDV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, LPV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, NFV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, DTG, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, EVG, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	INI, RAL, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NNRTI, DLV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, d4T, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	NRTI, ddI, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, ATV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, FPV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, RTV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, SQV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase	PI, TPV/r, Sensitive	2 Participants

Secondary

Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase

Time frame: Up to Week 148

Population: CVW resistance Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, RPV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, RPV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, DTG, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, DTG, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, DTG, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, EVG, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, EVG, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, EVG, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, RAL, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, RAL, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	INI, RAL, Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, DLV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, DLV, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, DLV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, EFV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, EFV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, EFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, ETR, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, ETR, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, ETR, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, NVP, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, NVP, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, NVP, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NNRTI, RPV, Resistant	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, 3TC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, 3TC, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, 3TC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ABC, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ABC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, FTC, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, FTC, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, TDF, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, TDF, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ZDV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ZDV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ZDV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, d4T, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, d4T, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ddI, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	NRTI, ddI, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, ATV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, ATV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, DRV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, DRV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, FPV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, FPV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, IDV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, IDV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, LPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, LPV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, LPV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, NFV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, NFV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, RTV, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, RTV, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, SQV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, SQV/r, Sensitive	2 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, TPV/r, Partially sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase	PI, TPV/r, Sensitive	2 Participants

Secondary

Number of Participants With Phenotypic Resistance-Early Switch Phase

Plasma samples were collected for drug resistance testing. Phenotypic Resistance data for the following drugs (DTG, RAL, EVG, RPV, ETR, 3TC, ABC, FTC, TDF, d4T, ddI, ATV/r, DRV/r, FPV/r, IDV/r, LPV/r, SQV/r, TPV/r) in participants Meeting CVW criteria has been presented.

Time frame: Up to Week 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, RPV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, RPV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, ETR, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, ETR, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, ETR, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, DLV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, DLV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, EFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, EFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, NVP, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NNRTI, NVP, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, 3TC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, 3TC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ABC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ABC, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ABC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, TDF, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, TDF, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, TDF, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, d4T, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, d4T, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ddI, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ddI, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ddI, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, FTC, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, FTC, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ZDV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	NRTI, ZDV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, ATV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, ATV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, DRV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, DRV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, DRV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, FPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, FPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, FPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, IDV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, IDV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, LPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, LPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, LPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, SQV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, SQV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, SQV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, TPV/r, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, TPV/r, Partially Sensitive	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, TPV/r, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, NFV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, NFV, Sensitive	1 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, RTV, Resistant	0 Participants
DTG + RPV	Number of Participants With Phenotypic Resistance-Early Switch Phase	PI, RTV, Sensitive	1 Participants

Secondary

Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 24 Using Snapshot Algorithm

Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity of DTG +RPV once daily compared to continuation of CAR. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

Time frame: Week 24

Population: ITT-E Population

Arm	Measure	Value (NUMBER)
DTG + RPV	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 24 Using Snapshot Algorithm	97 Percentage of participants
Current Antiretroviral Regimen (CAR)	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 24 Using Snapshot Algorithm	98 Percentage of participants

95% CI: [-4, 1.8]

Secondary

Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class

Percentage of participants with plasma HIV 1 RNA \< 50 c/mL at Week 48 using the FDA snapshot algorithm was assessed by Baseline third agent class to assess the impact of Baseline third agent class (INSTI, NNRTI, or PI) on efficacy, safety and tolerability of DTG +RPV compared to continuation of CAR. Plasma samples were collected for HIV-1 RNA at Baseline (Day 1), Week 4, 8, 12, 24, 36 and 48. The analysis was done using Cochran-Mantel Haenszel test stratified by current antiretroviral third-agent class.

Time frame: At Week 48

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (NUMBER)
DTG + RPV	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	NNRTI	97 Percentage of participants
DTG + RPV	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	INSTI	92 Percentage of participants
DTG + RPV	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	PI	91 Percentage of participants
Current Antiretroviral Regimen (CAR)	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	NNRTI	93 Percentage of participants
Current Antiretroviral Regimen (CAR)	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	INSTI	94 Percentage of participants
Current Antiretroviral Regimen (CAR)	Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class	PI	97 Percentage of participants

p-value: 0.179Chi-squared, Corrected

95% CI: [-1.6, 8.6]

95% CI: [-12.1, 7.4]

95% CI: [-13.9, 3.1]

Secondary

Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase

Two separate blood samples for DTG and RPV were collected pre-dose at Weeks 56, 76 and 100. Pre-dose concentrations of DTG and RPV at Weeks 56, 76 and 100 is summarized for the participants switching to DTG + RPV in the late switch phase.

Time frame: Pre-dose at Weeks 56, 76 and 100

Population: The analysis was performed on the Pharmacokinetic (PK) Parameter Population which consisted of all participants who received DTG +RPV and provided at least one evaluable estimate of predose concentration (C0). Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Week 56	1544.75 ug/ L	Standard Deviation 1049.595
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Week 76	1806.77 ug/ L	Standard Deviation 1019.3
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Week 100	1881.97 ug/ L	Standard Deviation 1160.587
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Week 56	77.27 ug/ L	Standard Deviation 38.931
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Week 76	91.46 ug/ L	Standard Deviation 48.568
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase	Week 100	90.89 ug/ L	Standard Deviation 47.762

Secondary

Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase

Two separate blood samples for DTG and RPV were collected pre-dose at Weeks 4, 24, 48, 56, 76 and 100. Pre-dose concentrations of DTG and RPV at Weeks 4, 24, 48, 56, 76 and 100 is summarized for the participants switching to DTG + RPV in the early+late switch phase.

Time frame: Pre-dose at Week 4, 24, 48, 56, 76 and 100

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 4	1578.88 ug/ L	Standard Deviation 1170.967
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 24	1447.23 ug/ L	Standard Deviation 917.677
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 48	1384.36 ug/ L	Standard Deviation 889.829
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 56	1637.74 ug/ L	Standard Deviation 1063.391
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 76	1507.81 ug/ L	Standard Deviation 913.263
DTG + RPV	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 100	1532.10 ug/ L	Standard Deviation 916.975
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 76	92.51 ug/ L	Standard Deviation 46.223
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 4	79.50 ug/ L	Standard Deviation 38.23
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 56	90.55 ug/ L	Standard Deviation 45.686
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 24	90.21 ug/ L	Standard Deviation 46.302
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 100	91.98 ug/ L	Standard Deviation 44.683
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase	Week 48	91.41 ug/ L	Standard Deviation 47.073

Secondary

Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV

Two blood samples were collected pre-dose for DTG and RPV at Weeks 2 and 8 only for the first 20 participants who switch from EFV or NVP to DTG+RPV, in addition to the pre-dose blood sample collected at Week 4 for all participants. One blood sample was collected pre-dose for EFV or NVP at Week 2 for the first 20 participants who switch from EFV or NVP to DTG + RPV. PK Parameter NNRTI Subset Extra Sampling Population consisted of the first approximately 20 participants in the PK Parameter NNRTI Subset population who have extra PK samples at weeks 2 and 8.

Time frame: Pre-dose at Weeks 2, 4 and 8

Population: PK Parameter NNRTI Subset extra sampling Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Week 2	834.58 ug/ L	Standard Deviation 639.622
DTG + RPV	Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Week 4	1218.23 ug/ L	Standard Deviation 842.703
DTG + RPV	Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Week 8	1472.50 ug/ L	Standard Deviation 818.774
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Week 2	57.342 ug/ L	Standard Deviation 29.5436
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Week 4	78.338 ug/ L	Standard Deviation 31.4825
Current Antiretroviral Regimen (CAR)	Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV	Week 8	79.652 ug/ L	Standard Deviation 40.7546

Other Pre-specified

Change From Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

Blood samples were collected for CD4+ cell count assessment by flow cytometry. Change from Baseline was calculated as value at indicated time point minus Baseline value.

Time frame: At Weeks 100 and 148

Population: ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Change From Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Week 100	55.9 Cells/mm^3	Standard Deviation 202.56
DTG + RPV	Change From Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-DTG+RPV Group Through Early and Late Switch Phase	Week 148	51.5 Cells/mm^3	Standard Deviation 205.98

Other Pre-specified

Change From LS Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-CAR Group Through Late Switch Phase

Blood samples were collected for CD4+ cell count assessment by flow cytometry. Change from LS Baseline was calculated as value at indicated time point minus LS Baseline value.

Time frame: LS Baseline (Week 48), Weeks 100 and 148

Population: LS ITT-E Population. Only those participants with data available at the specified time points were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
DTG + RPV	Change From LS Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-CAR Group Through Late Switch Phase	Week 100	20.9 Cells/mm^3	Standard Deviation 173.39
DTG + RPV	Change From LS Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-CAR Group Through Late Switch Phase	Week 148	6.5 Cells/mm^3	Standard Deviation 167.44

Other Pre-specified

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-CAR Group Through Late Switch Phase

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Percentage of participants with plasma HIV 1 RNA \< 50 c/mL using the FDA snapshot algorithm was assessed. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the window of the visit of interest.

Time frame: Weeks 100 and 148

Population: LS ITT-E Population

Arm	Measure	Group	Value (NUMBER)
DTG + RPV	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-CAR Group Through Late Switch Phase	Week 100	97 Percentage of participants
DTG + RPV	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-CAR Group Through Late Switch Phase	Week 148	93 Percentage of participants

Other Pre-specified

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-DTG+RPV Group Through Early and Late Switch Phase

Time frame: Weeks 100 and 148

Population: ITT-E Population

Arm	Measure	Group	Value (NUMBER)
DTG + RPV	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-DTG+RPV Group Through Early and Late Switch Phase	Week 100	89 Percentage of participants
DTG + RPV	Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-DTG+RPV Group Through Early and Late Switch Phase	Week 148	84 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm

Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class

Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase

Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase

Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase

Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase

Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class

Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48

Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48

Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48

Mean Change From Baseline in Cystatin C at Week 48

Mean Change From Baseline in D-Dimer at Week 48

Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48

Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48

Mean Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 48

Mean Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Week 48

Mean Change From Baseline in Interleukin 6 (IL-6) at Week 48

Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48

Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48

Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48

Mean Change From Baseline in Urine Phosphate at Week 48

Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class

Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)

Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase

Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase

Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase

Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase

Number of Participants With Genotypic Resistance-Early Switch Phase

Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks

Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class

Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks

Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase

Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase

Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase

Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase

Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase

Number of Participants With Phenotypic Resistance-Early Switch Phase

Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 24 Using Snapshot Algorithm

Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class

Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase

Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase

Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV

Change From Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

Change From LS Baseline in CD4+ Lymphocyte Count at Weeks 100 and 148-CAR Group Through Late Switch Phase

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-CAR Group Through Late Switch Phase

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Weeks 100 and 148 Using the Snapshot Algorithm-DTG+RPV Group Through Early and Late Switch Phase